Navigation Links
CureDM's Diabetes Therapy Achieves Major Development Milestone
Date:4/30/2008

WYNNEWOOD, Pa., April 30 /PRNewswire/ -- CureDM, Inc., a biopharmaceutical company developing new therapies that prevent, ameliorate, or reverse both type 1 and 2 diabetes, announces its achievement of a major drug development milestone for Human proIslet Peptide (HIP). CureDM has successfully stabilized HIP to improve its bioavailability with recent dose response studies indicating that the dosage used in man may be as much as 100-fold lower than the native form. HIP is a 14-amino acid human peptide derived from a specific human gene responsible for populating the pancreas with islets, which contain the cells that secrete insulin and other hormones necessary to prevent diabetes.

"Meeting this milestone has a significant impact on the commercial value of Human proIslet Peptide," according to Loraine V. Upham, CEO. "Not only does this mean lower costs associated with the manufacture and commercialization, but also potentially better safety and tolerability outcomes in human trials." CureDM has filed with the FDA and anticipates approval for commencement of human studies in early 2009.

Further studies are underway to determine just how low of a dose is possible. Previous studies have confirmed that the stabilization of HIP did not adversely affect the efficacy and demonstrated that normal glucose levels were achieved after 25 days of treatment and remained normal after the therapy was stopped.

About HIP

Human proIslet Peptide (HIP) stimulates the differentiation of pancreatic progenitor cells, which are present in the adult pancreas, into new insulin-producing islets. Each new islet contains pools of beta cells which make insulin. It is hypothesized that treatment with this therapeutic will restore human pancreatic function without the use of stem cells.

About CureDM

The CureDM approach to restore new insulin-producing cells through islet neogenesis can potentially reverse both type 1 and type 2 diabetes. Patients with type 1 diabetes will require pretreatment with an immune tolerance agent to protect new islets formed by HIP. CureDM, Inc., located at the Lankenau Institute for Medical Research on the Lankenau Hospital campus in Wynnewood, PA, is developing peptide therapeutics using a platform that combines bioinformatics, proteomics and Human Genome sequence data. This method has enabled the CureDM scientific team to determine the proteins involved in, and probable mechanisms of islet neogenesis in humans. For more information about CureDM, visit http://www.curedm.com.


'/>"/>
SOURCE CureDM, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Drug Combo Could Lower Diabetes Complications and Costs
2. Discovery Leads to Earlier Diagnosis of Type 1 Diabetes
3. People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
6. Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease
7. Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)
8. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
11. Reduced Lung Capacity Accelerates With Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New Jersey ... as well as advocacy for the state and region‘s technology businesses, hosted their ... The Council's Innovation Forecast event highlights innovation throughout the region from small to ...
Breaking Medicine News(10 mins):